IgG4-related ophthalmic disease

OncoHost's PROphet® Platform to Support Henlius US-Based Phase III Trial for Patients with Extensive-Stage Small Cell Lung Cancer

Retrieved on: 
Tuesday, October 3, 2023
Probability, IgG4-related ophthalmic disease, Therapy, Progression-free survival, Cancer, Data collection, Biomarker, Inflammation, Carboplatin, Immunotherapy, Inflammatory bowel disease, Etoposide, Protein, Mechanism, MD, Patient, Machine learning, Medicine, Mall of America, Caregiver, Safety, Disease, Pharmaceutical industry, OS

BINYAMINA, Israel , Oct. 3, 2023 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced a collaboration with Hengenix Biotech, Inc. (Henlius USA), affiliated with Shanghai Henlius Biotech, Inc., a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Henlius USA will utilize OncoHost's PROphet® platform to identify exploratory, correlative biomarkers for patients recruited in its comprehensive Phase III clinical trial (NCT05468489). The trial is evaluating the efficacy and safety of Serplulimab plus chemotherapy (carboplatin - etoposide) in previously untreated US-based patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

Key Points: 
  • Henlius USA will utilize OncoHost's PROphet® platform to identify exploratory, correlative biomarkers for patients recruited in its comprehensive Phase III clinical trial ( NCT05468489 ).
  • The trial is evaluating the efficacy and safety of Serplulimab plus chemotherapy (carboplatin - etoposide) in previously untreated US-based patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
  • "Our shared goal is to improve cancer patients' outcomes by developing robust, scientifically sound technologies to support them and their caregivers.
  • We believe that such collaborations hold the potential to bring new hope to those affected by this challenging disease."

Kriya Announces Exclusive License and Collaboration Agreement with Everads to Advance Gene Therapies for Prevalent Diseases in Ophthalmology Including Geographic Atrophy

Retrieved on: 
Wednesday, September 27, 2023
Drug delivery, Retina, Injection, CR2, Pediatrics, IgG4-related ophthalmic disease, Sclera, Eye, Geographic atrophy, Quality of life, Intravitreal injection, Inflammation, AAV, Complement, RESEARCH, Administration, C3, Choroid, Stanford University School of Medicine, Patient, CR1, PARK, Entrepreneurship, FDA, Therapy, Emotional dysregulation, Disease, Pharmaceutical industry, Medical device, Vaccine, Ophthalmology, Kriyā, C5

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies for conditions affecting millions of people around the world, has entered into an exclusive license, collaboration and supply agreement with Everads Therapy, Ltd (“Everads”) to advance Kriya’s portfolio of gene therapies for retinal diseases using Everads' suprachoroidal delivery device. Everads is a private biotech company that has developed a novel technology enabling targeted delivery of therapies to the retina via the suprachoroidal space, an anatomical compartment located between the sclera and choroid that traverses the circumference of the posterior segment of the eye. Suprachoroidal delivery is an emerging, non-surgical route of administration in ophthalmology. Specifically in delivery of gene therapy, this route of administration offers the potential to enhance the efficiency of gene therapy delivery to the retina while minimizing intraocular inflammation.

Key Points: 
  • Specifically in delivery of gene therapy, this route of administration offers the potential to enhance the efficiency of gene therapy delivery to the retina while minimizing intraocular inflammation.
  • The transaction enables Kriya’s access to Everads’ suprachoroidal delivery technology to deliver multiple prespecified gene therapy product candidates for several ophthalmic diseases, including those involving the complement cascade.
  • “I am quite optimistic and convinced that innovative therapies will continue to improve the lives of people with geographic atrophy and other serious ophthalmic diseases.
  • A gene therapy targeting the C3 and C5 pathways delivered by a suprachoroidal injection may be a significant improvement in the treatment of geographic atrophy.”

Exploring the Demodex Blepharitis Market: Clinical Viewpoints, Pipeline Evaluation, and Market Access Services | Disease Landscape Insights

Retrieved on: 
Monday, September 11, 2023
Infection, Pharma, Chalazion, Eyelash, Ocular rosacea, Signs and symptoms, Research, Inflammation, IgG4-related ophthalmic disease, Causes, Eyelid, DLI, Biological soil crust, Immune system, Growth, MITES, Ageing, Patient, Itch, Diagnosis, Stye, Meibomian gland dysfunction, Gland, FDA, R, Red, NIH, Skin, NME, Disease, Cosmetics, Agriculture, Medical device, Pharmaceutical industry, Demodex

Demodex Blepharitis is an inflammatory eye disorder caused by the uncontrollable growth of tiny mites known as Demodex on our eyelids.

Key Points: 
  • Demodex Blepharitis is an inflammatory eye disorder caused by the uncontrollable growth of tiny mites known as Demodex on our eyelids.
  • We at Disease Landscape Insights (DLI) aim to assist our clientele in understanding the characteristics of this disease and help them develop cutting edge treatment solutions.
  • Unlocking Insights into Demodex Blepharitis – From Research to Treatment Solutions, Dive Deeper into Managing this Eye Condition.
  • According to a data released by NIH, around 41% to 70% of the world's population are affected or highly prone to Demodex Blepharitis .

HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies

Retrieved on: 
Monday, August 28, 2023
IgG4-related ophthalmic disease, Neoplasm, Research, Patient, Cancer, FC, Pharmaceutical industry

The collaboration aims to expand the application of each company's platform by developing novel cancer immunotherapies, including those tumors resistant to anti-PD-1/L1 immunotherapies, to accelerate their respective pipeline of innovative immunotherapy medicines.

Key Points: 
  • The collaboration aims to expand the application of each company's platform by developing novel cancer immunotherapies, including those tumors resistant to anti-PD-1/L1 immunotherapies, to accelerate their respective pipeline of innovative immunotherapy medicines.
  • Mr. Jason Zhu, Chief Executive Officer, President, and Chief Financial Officer of Henlius, said, "Henlius is dedicated to providing affordable and innovative biologics for patients around the world.
  • Taking innovation as a driver, HanchorBio has quickly built its differentiated advantages and stands out in the field of onco-immunotherapy.
  • This collaboration will allow Henlius to further accelerate our practice of affordable innovation and benefit more patients worldwide by fully leveraging HanchorBio's leading-edge technology and R&D platform."

The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed

Retrieved on: 
Wednesday, July 26, 2023
Bevacizumab, IgG4-related ophthalmic disease, Clinical trial, Research, IVT, VEGF, Eye, Patient, European, Visual acuity, Death, KDR, Endothelium, Safety, Pharmaceutical industry, Vaccine, EU

This single-arm, open-label, multicentre, phase I/II study aimed to evaluate the safety and preliminary efficacy of EB12-20145P (HLX04-O) via intravitreal injection (IVT) in patients with active wet age-related macular degeneration (wAMD).

Key Points: 
  • This single-arm, open-label, multicentre, phase I/II study aimed to evaluate the safety and preliminary efficacy of EB12-20145P (HLX04-O) via intravitreal injection (IVT) in patients with active wet age-related macular degeneration (wAMD).
  • Part 2 was a single-arm, open-label, multicentre, phase II study and 20 patients (including 6 patients from part 1) were enrolled in this part.
  • As of now, the clinical trial applications of EB12-20145P (HLX04-O) had been approved in Singapore and other countries and regions.
  • EB12-20145P (HLX04-O) has the potential to be one of the first bevacizumab approved for use in ophthalmic diseases, benefiting more patients with eye diseases worldwide.

Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets

Retrieved on: 
Tuesday, July 11, 2023
Retina, IgG4-related ophthalmic disease, Therapy, Visual impairment, Regeneration, Research, Paratriathlon, Diabetic retinopathy, AAV, MD, Patient, R100, Entrepreneurship, Russian–Ukrainian Friendship Treaty, TSE, Pharmaceutical industry, Vaccine, Astellas Pharma

R100 is an adeno-associated virus (AAV) vector invented by 4DMT for intravitreal delivery.

Key Points: 
  • R100 is an adeno-associated virus (AAV) vector invented by 4DMT for intravitreal delivery.
  • It has the ability to penetrate the internal limiting membrane barrier and to efficiently transduce the entire retina, resulting in robust transgene expression within retinal cells.
  • All three 4DMT clinical-stage ophthalmic product candidates utilize the R100 vector, including 4D-150 for wet age-related macular degeneration and diabetic macular edema.
  • Under the terms of the agreement, 4DMT will provide its proprietary R100 vector technology to Astellas to deliver Astellas' unique genetic payloads for the treatment of rare monogenic diseases.

EQS-News: Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease

Retrieved on: 
Friday, June 2, 2023
BIO, Therapy, IgG4-related ophthalmic disease, Senior, CMC, Geographic atrophy, ATMP, AAV, CDMO, Eye, Patient, BD, Vaccine, Pharmaceutical industry

Under the agreement, Rentschler Biopharma’s ATMP site in Stevenage, UK, will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel gene therapy for the treatment of geographic atrophy.

Key Points: 
  • Under the agreement, Rentschler Biopharma’s ATMP site in Stevenage, UK, will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel gene therapy for the treatment of geographic atrophy.
  • Dr. Katie Binley, Chief Scientific Officer of Ikarovec, said: “We are delighted to collaborate with Rentschler Biopharma on our lead program.
  • Dr. Christian Schetter, Chief Scientific Officer of Rentschler Biopharma, added: “With Rentschler Biopharma’s ATMP offering, we aim to address an important gap in specific support for innovative, early-stage cell and gene therapy programs.
  • Ikarovec and its novel candidate are a perfect fit for our services.

Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease

Retrieved on: 
Thursday, June 1, 2023
BIO, Therapy, IgG4-related ophthalmic disease, Senior, CMC, Geographic atrophy, ATMP, AAV, CDMO, Eye, Patient, NORWICH, BD, Vaccine, Pharmaceutical industry

Under the agreement, Rentschler Biopharma’s ATMP site in Stevenage, UK, will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel gene therapy for the treatment of geographic atrophy.

Key Points: 
  • Under the agreement, Rentschler Biopharma’s ATMP site in Stevenage, UK, will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel gene therapy for the treatment of geographic atrophy.
  • Dr. Katie Binley, Chief Scientific Officer of Ikarovec, said: “We are delighted to collaborate with Rentschler Biopharma on our lead program.
  • Dr. Christian Schetter, Chief Scientific Officer of Rentschler Biopharma, added: “With Rentschler Biopharma’s ATMP offering, we aim to address an important gap in specific support for innovative, early-stage cell and gene therapy programs.
  • Ikarovec and its novel candidate are a perfect fit for our services.

Accelerating Gene Therapy for Ophthalmic Diseases, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Friday, May 19, 2023
Ophthalmology, Artificial intelligence, Quality of life, IgG4-related ophthalmic disease, Therapy, Research, Patient, Safety, AAV, Medical device

TORONTO, Ontario, May 19, 2023 /PRNewswire-PRWeb/ -- There are a large number of patients with hereditary ophthalmic diseases worldwide, with gene therapy drugs emerging as a powerful therapeutic tool in ophthalmology due to the limited efficacy of traditional treatments. As of 2021, ophthalmology ranks second in the gene therapy pipeline according to the number of treatments in development. There are many gene therapy drugs currently on the market, but basic research and clinical translation in ophthalmology face many difficulties, such as complicated operations, a long production period for experimental models and expensive equipment.

Key Points: 
  • In this free webinar, learn about improving the quality of life and bringing more effective and affordable treatments to patients through one-stop R&D solutions for ophthalmology gene therapy.
  • Attendees will gain insights into the rapid advancements in preclinical ophthalmic gene therapy research.
  • As of 2021, ophthalmology ranks second in the gene therapy pipeline according to the number of treatments in development.
  • Register for this webinar to learn about the rapid advancements in preclinical ophthalmic gene therapy research, such as how AI-guided AAV design tools can help accelerate development of effective therapeutics to patients with ophthalmic diseases.

CO2 Medical Laser Systems Global Market Report 2023: Growing Demand for Cosmetic Dentistry and Aesthetic Procedures Bolsters Sector - ResearchAndMarkets.com

Retrieved on: 
Monday, March 20, 2023
Health, Dental, Medical Devices, Dentistry, Infection, Blepharoplasty, United States National Library of Medicine, Stent, Gynaecology, US Foods, Obesity, National Centre for Infectious Diseases, Bleeding, IgG4-related ophthalmic disease, Prevalence, Diabetes, Dermatitis, Food, NCBI, Cardiovascular disease, Skin, Woman, National Center for Biotechnology Information, CVD, Polycystic ovary syndrome, USD, Heart, American Society of Plastic Surgeons, National library, Dermatology, Laser, Urology, Developed country, Application, PCOS, Ophthalmology, Oral hygiene, Conditional sentence, Growth, Region, Plastic, FDA, Neurology, CO2, World Health Organization, Medical device, Health care, Veterinary medicine, Pharmaceutical industry

The "CO2 Medical Laser Systems Market by Type, by Application, by End User, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "CO2 Medical Laser Systems Market by Type, by Application, by End User, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.
  • Increasing healthcare spending, growing demand for cosmetic dentistry and improved aesthetic appearance, and adoption of technological advancements are other factors supporting the market growth.
  • The number of CVD-related preventive and therapeutic procedures has increased recently, which has boosted demand for CO2 laser cutting equipment.
  • In 2022, North America region accounted for the highest revenue in the CO2 medical laser market during the forecast period.